Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1 Pancreatic Neoplasms 1 Gastric Adenocarcinoma 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Arthritis, Rheumatoid 1

Interventions

Oxaliplatin 290 Capecitabine 206 Fluorouracil 181 Cisplatin 168 Docetaxel 138 S 1 (combination) 132 Paclitaxel 121 Leucovorin 116 Irinotecan 106 pembrolizumab 103 Trastuzumab 71 apatinib 56 Nivolumab 56 sintilimab 45 Drug Therapy 43 Surgical Procedures, Operative 37 Radiotherapy 37 Bevacizumab 37 Ramucirumab 34 titanium silicide 31 Hyperthermic Intraperitoneal Chemotherapy 30 Epirubicin 30 Carboplatin 30 tislelizumab 28 Cyclophosphamide 27 XELOX 24 Tegafur 23 Folfox protocol 22 Albumin-Bound Paclitaxel 22 camrelizumab 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Stomach Neoplasms × andecaliximab × Clear all

NCT02545504 2020-05-26

GAMMA-1

Gilead Sciences

Phase 3 Completed

432 enrolled 19 charts

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡